Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study.
Maria FleseriuStephan PetersennBeverly M K BillerPinar KadiogluChristophe De BlockGuy T'SjoenMarie-Christine VantyghemLibuse TauchmanovaJudi WojnaMichael RoughtonAndré LacroixJohn Newell-PricePublished in: Clinical endocrinology (2019)
Long-acting pasireotide provided sustained biochemical and clinical improvements, with no new safety signals emerging, supporting its use as an effective long-term therapy for CD.